Immuneering Corporation, a clinical-stage oncology company, has announced a private placement of securities expected to generate approximately $25 million in gross proceeds. The transaction involves the sale of 6,329,113 unregistered shares of Class A common stock at $3.95 per share, alongside purchase warrants for an additional 2,848,096 shares at an exercise price of $5.50 per share. The private placement is subject to customary closing conditions, with the funds set to support the company's ongoing clinical efforts, particularly in advancing their treatment for pancreatic cancer. The investment reflects strong interest from top-tier institutional and accredited investors following promising survival data from Immuneering's Phase 2a trial of atebimetinib.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.